SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Aug 14, 2007 -- Novacea, Inc. (NasdaqGM:NOVC - News) today reported financial results for the second quarter of 2007. The company’s net loss for the second quarter of 2007 was $16.0 million, or $0.69 per share. As of June 30, 2007, cash, cash equivalents and marketable securities totaled $46.2 million. In early July, the company received $72 million from Schering-Plough under the terms of the previously announced worldwide development and commercialization agreement for Asentar(TM), comprised of upfront payments totaling $60 million and an additional $12 million from the purchase by Schering-Plough of Novacea common stock. The company also today announced its plans to augment the robustness of its ASCENT-2 Phase 3 trial for androgen-independent prostate cancer, or AIPC.
